Elsevier

Vaccine

Volume 35, Issue 34, 3 August 2017, Pages 4298-4306
Vaccine

Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

https://doi.org/10.1016/j.vaccine.2017.06.088Get rights and content
Under a Creative Commons license
open access

Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination.

We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons.

We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: −35 to 64), 8% (95%CI: −94 to 56) and 33% (95%CI: −43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was −1% (95%CI: −80 to 43), 37% (95%CI: 7–57) and 43% (95%CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively.

Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.

Cited by (0)

1

InNHOVE/I-MOVE+working group: EpiConcept: M. Valenciano; France: N. Lenzi, Z. Lesieur, P. Loulergue (Innovative clinical research network in vaccinology (I-REIVAC), CIC De Vaccinologie, Cochin-Pasteur, Paris), F. Galtier, M. Ray, V. Foulongne, F. Letois, C. Merle (CHU de Montpellier), P. Vanhems (Hôpital Edouard Herriot, Lyon, IREIVAC), B. Lina (Université Lyon 1, Centre National de Référence virus influenza France Sud, Lyon, France); Navarra : I. Casado, J. Diaz-González, M. Guevara, I. Martínez-Baz, L. Fernandino (Instituto de Salud Pública de Navarra, IdiSNA, CIBERESP, Pamplona), A. Navascués, C. Ezpeleta, J. Chamorro (Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain), L. Barrado (Hospital de Estella, Spain), MT Ortega (Hospital de Tudela, Spain); Italy : K. de Gaetano Donati, R. Cauda, C. Donato, F. Taccari, L. Campana, R. Santangelo (Catholic University, Policlinico Gemelli, Rome), F. Perlasca, G. Fichera, M. Dara, (Ospedale di Circolo e Fondazione Macchi, Varese), L. Iacoviello, (IRCCS Neuromed, Pozzilli), M. Olivieri (Campobasso, EPICOMED Research, srl), V. Alfonsi, A. Bella, S. Puzelli, MR Castrucci (Istituto Superiore di Sanità, Rome), A. Orsi, F. Ansaldi (IRCCS AOU San Martino- IST, Genoa hospital. Department of Health Sciences, University of Genoa), I. Manini, E. Montomoli (Department of Molecular and Developmental Medicine. Lab Molecular Epidemiology - University of Siena), M. Chironna, C. Germinario (Policlinico Hospital, Department of Biomedical Science, University of Bari); Valencia: J. Díez-Domingo (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia), Barrenengoa Sañudo (Hospital General de Castellón, Castellón), C. Carratalá Munuera (Hospital San Juan, Alicante), P. Correcher Medina (Hospital Lluis Alcanyis, Xàtiva), V. Gil Guillén (Hospital General de Elda, Elda), R. Larrea González (Hospital General de Castellón, Castellón), R. Limón Ramírez (Hospital de la Plana, Vila-real), JL. Micó Esparza (Hospital Arnau de Vilanova, Valencia), J. Mollar Maseres, MC. Otero Reigada (Hospital Universitario y Politécnico La Fe, Valencia), M. Tortajada Girbés (Hospital Doctor Peset, Valencia), G. Schwarz Chavarri (Hospital General de Alicante, Alicante); Lithuania: A. Ambrozaitis, L. Jancoriene, B. Zablockiene, K. Zagminas (Vilnius University Faculty of Medicine, Vilnius, Lithuania), M. Aukse, G. Damuleviciene, R. Grimalauskaite, M. Kuliese, V. Lesauskaite, D. Velyvyte (Lithuanian University of Health Sciences, Kaunas, Lithuania), H. Niesters, RP. Stolk, K. Zagminas (University Medical Centre Groningen, the Netherlands), J. Rahamat-Langendoen (Radboud university medical centre, Nijmegen, the Netherlands); Spain: A. Gherasim (National Centre of Epidemiology, Institute of Health Carlos III, Madrid), F. Pozo (National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Madrid), J. Altzibar, JG Arraras (Subdirección de Salud Pública de Gipuzkoa, País Vasco), G. Cilla (Hospital Universitario Donostia, País Vasco), E. Marco, M. Vidal Garcia (Dirección General de Salud Pública, Aragón), M. Omeñaca (Hospital Universitario Miguel Servet, Zaragoza); Romania: AE. Ivanciuc, E.Lupulescu, M.Lazar, CM Cherciu, C. Tecu, ME Mihai (NIR Cantacuzino, Bucharest,), M. Nitescu (UMF Carol Davila Bucharest, INBI Matei Bals, Bucharest), D. Leca (UMF Gr. Popa Iasi, Infectious Diseases Hospital Sf. Parascheva, Iasi), E. Ceausu (UMF Carol Davila Bucharest, Infectious Diseases Hospital V. Babes, Bucharest); Finland: H. Nohynek (Vaccination Programme Unit, National Institute for Health and Welfare (THL)), N. Ikonen, A. Haveri (Viral Infections Unit, National Institute for Health and Welfare (THL)); Portugal: V.Gomez, B. Nunes, AP. Rodrigues (Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, MJ. Peres (Centro Hospitalar de Setúbal, Setúbal); Croatia: V. Višekruna Vučina, B. Kaić, IP. Novosel, G. Petrović (Epidemiology Service, Croatian Institute of Public Health, Zagreb); Hungary: A. Ferenczi, B. Oroszi (National Centre for Epidemiology, Department of Communicable Disease prevention and Surveillance, Budapest); Poland : MR. Korczyńska, LB Brydak, (National Influenza Centre, National Institute of Public Health-National Institute of Hygiene, Warsaw), R. Cieślik-Tarkota, (Department of Epidemiology, Voivodeship Sanitarian- Epidemiological Station in Katowice, Katowice), B. Rozwadowska, Department of Laboratory, Voivodeship Sanitarian- Epidemiological Station in Katowice, Katowice), G. Skolimowska (Regional Hospital in Siedlce, Siedlce), D. Hulbój (Regional Hospital in Bielsko-Biała, Bielsko-Biała), A. Jakubik (Regional Hospital in Warsaw “Szpital Praski”, Warsaw); The Netherlands: A. Meijer, A.B. van Gageldonk-Lafeber (Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for public health and the Environment (RIVM).